Assessment of Suppression of Cutaneous Allergic Responses and Pruritus by Topical Doxycycline

• Status: Active, not recruiting
• Trial end date: 2022-05-14
• Target enrollment: 0
• Participant gender: All

Summary

Investigators will study the effects of topical doxycycline on cutaneous allergic early and late phase responses by determining allergen skin responses in each subject after a single application to allergen induced allergic swelling of 2% doxycycline in emollient.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: State University of New York - Downstate Medical Center
• Treatments: Doxycycline; Petrolatum

Criteria

Inclusion Criteria:

• Adult (ages 18-75) outpatients with diagnosis of allergic rhino-conjunctivitis and/or asthma who have previously undergone epicutaneous skin prick testing with detection of at least one allergen positive, and who may or may not have had a serum IgE level done as part of their routine evaluation.

Exclusion Criteria:

• Subjects unable/unwilling to undergo cessation of oral antihistamines for five days prior to testing.

• Current use of oral steroids or other systemic immunosuppressants, including omalizumab (anti-IgE therapy) and anti-IL-5 therapy.

• Allergic asthmatics with current uncontrolled asthma.

• Pregnant women